16 results about "Mitochondrial protein" patented technology

The invention discloses engineering mitochondria enriched with alpha2delta2 protein, the expression level of the alpha2delta2 protein in the mitochondria is higher than that of natural mitochondria, the expression quantity of the alpha2delta2 protein is 15-40 times that of the natural mitochondria, and the alpha2delta2 protein is enriched in the outer membrane of the mitochondria. The invention also discloses a preparation method of the engineered mitochondria enriched with the alpha2delta2 protein. The invention also discloses an application of the engineered mitochondria enriched with the alpha2delta2 protein in preparation of medicines for preventing and / or treating fibrosis diseases. In-vitro experiments prove that the engineered mitochondria can significantly enhance the ability of inhibiting fibroblast activation and collagen secretion, and the effect of the engineered mitochondria is far better than that of common mitochondria. The invention provides a brand-new and effective organelle level treatment scheme for solving the clinical problem of fibrosis.

The invention discloses a phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting. The phototherapy nano-drug is ATO / CR nano-particles formed by self-assembling a compound CR and atorvaquone under the action of distearoyl phosphatidyl ethanolamine-polyethylene glycol; the structure of the compound CR is shown as a formula I in the specification. The invention discloses an application of the phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting in preparation of drugs for treating tumors. The phototherapy nano-drug can target mitochondria and STAT3 protein in tumor cells through ATO, and can also passively target tumor sites through the high-permeability long-retention effect of nano-particles, so that more nano-therapeutic agents are enriched around tumors, and the curative effect is improved. The phototherapy nano-drug provided by the invention has good photothermal performance, can effectively enhance the PTT effect of gastric cancer, and exerts the tumor synergistic treatment ability by promoting cell apoptosis, inhibiting angiogenesis and hindering the cell cycle.

The invention discloses application of insect COX5B protein or related biological materials thereof in preparation of products for resisting black-streaked dwarf virus infection and products for controlling insects to spread black-streaked dwarf viruses. The invention also discloses an application of the specific antibody of the insect COX5B protein in detection of black-streaked dwarf virus in an insect body. The invention also discloses a method for controlling transmission of southern rice black-streaked dwarf virus by sogatella furcifera. It is found that the sogatella furcifera COX5B protein can inhibit acquisition and copying of SRBSDV, so that accumulation of the SRBSDV is inhibited, host survival is enhanced, the COX5B protein can inhibit propagation of the SRBSDV in sogatella furcifera, and the COX5B protein can be used for preparing products for resisting black-streaked dwarf virus infection and products for controlling propagation of the black-streaked dwarf virus by insects so as to improve the black-streaked dwarf virus resistance of crops; the kit can also be used for detecting black-streaked dwarf viruses in insect bodies.

The application discloses an application of an ND-42 related plasmid in preparation of a Drosophila mitochondrial protein expression kit, and the kit is mainly designed for a preparation method of mitochondrial related protein expression in S2 cells for the ND-42 protein. The kit constructs a pUAS-attB-3xHA-ND-42CDS full-length plasmid, a pUAS-attB-3xHA-ND-42-DNK-dom plasmid and a pUAS-attB-3xFlag-Nap1CDS full-length plasmid. The kit mainly uses a UAS-Gal4 system to realize the expression of the ND-42 protein, the DNK domain of the ND-42 protein and the Nap1 protein. The results of immunoprecipitation and Western blotting show that the Nap1 protein can strongly interact with the ND-42 protein. Further experimental observation shows that the Nap1 protein can also strongly physically combine with the DNK domain of the ND-42 protein. The kit can provide an important research method for the function and mechanism exploration of the mitochondrial related protein.

The invention discloses a novel quinoline derivative probe (HD) as well as a preparation method and application thereof, and belongs to the technical field of fluorescent probes. The probe has two different spectral switching modes, and this single molecule / dual mode design effectively eliminates the obstacle to deliver the two different probes to the mitochondria, as well as the additional toxicity associated with multi-probe coupling. The fluorescence behavior of HD in mitochondria proves the special ability of HD in monitoring protein and nucleic acid dynamics in living cells. Mitochondrial protein and nucleic acid are fused to form nucleoprotein, and the nucleoprotein is dissociated and is in a balanced state under normal conditions. This balance regulates the activities necessary for the mitochondria, including fusion and division. The invention opens up a new thought for reasonable design of the mitochondrial nucleoprotein dynamic super-resolution imaging probe, and lays a foundation for further research on the action of interaction of mitochondrial nucleic acid and protein in the pathogenesis and treatment strategy of Parkinson's disease.

There is provided a method of promoting survival and / or function of an amyotrophic lateral sclerosis (ALS) or ALS-like motor, the method comprising contacting the motor neuron with an agent capable of reducing mitochondrial protein acetylation, particularly an agent selected from a deacetylase activator, such as nicotinamide (NAM) and 7-hydroxy-3-(4′-methoxyphenyl) coumarin (C12), or an acetyltransferase inhibitor, such as GCN5L1 siRNA of SEQ ID NO: 1. Also provided are related agents, oligonucleotides, uses and methods of identifying agents.

The invention relates to the technical field of bioinformatics, and discloses a HiFi data organelle genome one-key assembly method which comprises the following steps: step 1, randomly and uniformly sampling whole genome HiFi sequencing data based on file size; 2, estimating the sequencing depth by using the amino acid sequence of the conserved mitochondrial protein coding gene, and determining a filtering threshold value; 3, obtaining a high-frequency k-mer set based on a prefix classification strategy, and screening effective read segments; step 4, carrying out organelle genome assembly on the screened read segments by using a Flye assembly tool; and 5, generating an interactive quality evaluation report. According to the HiFi data organelle genome one-key assembly method, through the five steps, the advantages of high efficiency, low resource demand, usability, cross-platform compatibility, comprehensive quality evaluation and wide applicability are achieved.

The present invention provides: a compound having a cancer immunity activating effect and represented by formula (I) [wherein the ring A is as defined in the description] or a pharmaceutically acceptable salt thereof (excluding a compound represeneted by [Chemical formula 2]); and a pharmaceutical composition which has higher biological stability than that of spermidine, can selectively bind to a mitochondrial protein to enhance the activation of FAO, and improves anti-tumor immunity in a cancer immunotherapy, the pharmaceutical composition containing the compound or the pharmaceutically acceptable salt.

Provided herein are methods, kits, and assays for identifying and quantifying a mitochondrial protein in a sample using mass spectrometry. Also provided herein are methods, kits, and assays for determining a mitochondrial protein biomarker signature for a subject using mass spectrometry.

HTS screening was performed regarding cell proliferation, one of symptoms of senescence. As a result, KB1541, which was the most effective on cell proliferation, was earned. The present invention described how the compound regulates cell proliferation and senescence. The present invention uncovered what proteins interacted with the compound using streptavidin-magnetic beads after treating with biotin-connected KB1541. Consequently, it was identified that mitochondrial proteins interacted with the compound. In ATP assay, electron microscope and IP assay, the inventors identified that the compound regulated mitochondrial proteins and thereby increased ATP production as well as recovered senescence.

The invention relates to the technical field of biomedical material preparation, in particular to a protein degradation chimera with a mitochondrial targeted degradation function as well as a preparation method and application of the protein degradation chimera. The chemical formula of the protein degradation chimera disclosed by the invention is C45H63BFN5O10S. According to the ROS response activated mitochondrial protein degradation chimera designed by the invention, space-time selective activation of a tumor part is realized through combined administration of the lipid nanoparticles and the microneedle patch, mitochondrial related proteins can be efficiently degraded, ICD can be induced, and an anti-tumor immune curative effect can be remarkably enhanced. The system provides a new material and a new strategy for tumor immunotherapy, and has good clinical transformation potential.

The present disclosure provides methods for treating or preventing diseases in which α-synuclein is pathologically implicated, through increasing the expression or activity of a mitochondrial protease that degrades α-synuclein. Agents for use in such methods are also disclosed.

The invention provides application of an ACLY gene medicine in preparation of a medicine for treating and preventing cardiomyopathy. The sequence of the ACLY gene is SEQ ID NO.1, and the cardiomyopathy comprises cardiac dysfunction caused by isoprenaline and thoracic aorta constriction. A cardiomyopathy drug AAV9-cTnT-ACLY taking ACLY in mitochondria as a drug target is developed by researching the relationship between ACLY and the occurrence mechanism of cardiomyopathy, the drug is based on an AAV9 adeno-associated virus vector, an ACLY gene segment is inserted into the vector, and finally animal experiments are performed to verify the effect of the drug. It is found that the high-expression mitochondrial targeting ACLY can significantly improve the expression and activity of ACLY in myocardial cells, inhibit mitochondrial protein acetylation and significantly improve the heart function of mice, and has very high clinical value.

The application provides application of a small molecule compound S89 in preparation of a drug for treating diseases related to mitochondrial abnormalities, and belongs to the field of medicines. The small molecule compound S89 can enhance the enzyme activity of mitochondrial MFN1 protein, has the effects of promoting mitochondrial fusion of cells, restoring mitochondrial morphology and function, and can improve axon degeneration of motor neurons of CMT2A patients, and can be used for preparing a drug for treating CMT2A type Charcot-Marie-Tooth disease and a heart ischemia-reperfusion injury syndrome, and can also be used for preparing a drug for inhibiting proliferation of lung cancer cells.

The present invention discloses superoxide-specific quinone methide precursors (QMP-SOs) that enable proximity labeling and chemoproteomics to investigate superoxide redox biology. QMP-SOs are activated by superoxide to generate a reactive quinone methide intermediate that covalently tags nearby proteins. These probes exhibit high selectivity toward superoxide over other ROS, enabling protein labeling in superoxide-rich cellular compartments. QMP-SOs are compatible with fluorescence imaging and tandem mass tag (TMT)-based mass spectrometry, facilitating visualization of superoxide dynamics and identification of superoxide-regulated proteins. In menadione-treated HepG2 cells, QMP-SO-TMT profiling identified mitochondrial proteins including DJ-1 and DLDH as redox-sensitive targets, linking superoxide stress to cell survival and metabolism. The QMP-SO platform uniquely combines spatial proximity labeling with superoxide specificity, allowing previously inaccessible insights into dynamic and localized redox signaling. This invention is broadly applicable in studying superoxide-mediated processes and holds potential for therapeutic target discovery in diseases driven by oxidative stress, including cancer, aging, and neurodegeneration.

The invention provides nano-particles combined with tubulin disrupting agent dimer and copper death medicine as well as a preparation method and application of the nano-particles, and belongs to the field of biological medicine. The invention provides a nanoparticle combining a tubulin disrupting agent dimer and a copper death drug. The microtubulin destroying agent can be used for enhancing the sensitivity of tumor cells to oxidative damage by destroying a cell microtubule structure and inducing oxidative stress and blood flow occlusion; the copper death drug promotes copper ion accumulation, causes mitochondrial protein aggregation and dysfunction, and finally induces cell death. The two medicines are combined for use, so that a remarkable synergistic anti-tumor effect can be generated, and the treatment efficiency is remarkably improved; meanwhile, after the two drugs are prepared into the nanoparticles, the selectivity index of the nanoparticles for resisting tumors is good, and the toxic and side effects on cells are small. The method has wide clinical transformation prospects and important social and economic values.